High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
about
The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDSCombining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioProteasome inhibitors in the treatment of multiple myelomaA phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a reviewCellular therapy following allogeneic stem-cell transplantation.Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.New targets and treatments in multiple myeloma: Src family kinases as central regulators of disease progression.Proteasomal regulation of pulmonary fibrosis.Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.Cellular immunotherapy for plasma cell myeloma.Allogeneic transplantation in multiple myeloma.State-of-the-art acute and chronic GVHD treatment.Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.New and emerging therapies for acute and chronic graft versus host disease.EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
P2860
Q30248842-EFB0C78C-97C6-44AC-8994-FAA74C449E34Q30486842-81707050-A0BE-4624-B520-11C1299BA36BQ33416169-12C0F289-5A8E-4320-8EB4-3440C6572D74Q33733541-042DA567-38BA-4464-B36C-17B69E998827Q33783925-A31AE7D1-1EE1-4391-A347-6A45B92C79DAQ34044024-767B2C05-3813-44AD-877D-EAFD954A2D6EQ34202277-49B14904-E8D2-4843-94AB-CF25413F9E30Q34611676-46A590E1-AB04-4C22-BB05-829150C21545Q35737769-D7F4466B-24D2-46C1-A633-92837669E070Q36408216-4FF1226F-213C-445D-B123-99728187A292Q36612643-48A4BB4C-A764-438B-A00A-D18E8022C58FQ36805875-D48F12BA-5CC7-4F75-81B0-EFBC6AE50A93Q37340398-790D80C6-C5A1-4918-BA42-40335E166328Q37693531-A01C09A2-9DB4-4553-B910-8362196F6350Q37822742-6A278308-35F1-456D-96A3-54FF8931A5FBQ38104288-8CD1F666-04B6-44E9-999E-B80E60014573Q38162280-5C4A7F0A-C762-40B1-A49F-1E4EED49EFA1Q38416376-CBD10326-14F9-4280-990D-E0850F89109DQ38417073-C3208C6E-5832-4E24-A95D-469FBE314577Q39174731-316C29A3-0C5C-4383-96B7-DE73FAEF2B1EQ45836702-CCF8F87D-3EF1-4D94-B6C4-AADCE9F6D9E8Q49238507-894A2703-BB01-444B-8EEE-90D5AD279664Q53310170-6457793A-9CE5-4DA3-A0B0-6CE80BF609E8
P2860
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
High response rate and improve ...... antation for multiple myeloma.
@ast
High response rate and improve ...... antation for multiple myeloma.
@en
type
label
High response rate and improve ...... antation for multiple myeloma.
@ast
High response rate and improve ...... antation for multiple myeloma.
@en
prefLabel
High response rate and improve ...... antation for multiple myeloma.
@ast
High response rate and improve ...... antation for multiple myeloma.
@en
P2093
P356
P1433
P1476
High response rate and improve ...... antation for multiple myeloma.
@en
P2093
Arnon Nagler
Avichai Shimoni
Catherine Faucher
Daniela Revesz
Didier Blaise
Franck E Nicolini
Hugues de Lavallade
Izhar Hardan
Jean El-Cheikh
Mauricette Michallet
P304
P356
10.3324/HAEMATOL.12184
P577
2008-02-20T00:00:00Z